Liquid Biopsy Software Market (2026-2036)
The global liquid biopsy software market was valued at USD 1.4 billion in 2026. This market is expected to reach USD 5.2 billion by 2036, growing at a CAGR of 13.4% during the forecast period 2026–2036.
- Published
- Jun 2026
- Pages
- 267
- Format
- PDF + Excel
- Report ID
- MRHC - 1042015
- Base year
- 2025
- 2026 · ESTIMATED
- $1.40B
- 2036
- $5.20B
- CAGR 2026–2036
- 13.4%
2025 baseline · 2026–2036 forecast at 13.4% CAGR · hover a bar for the value
Key highlights
The global liquid biopsy software market is projected to reach USD 5.2 million by 2036.
The market is expected to grow at a CAGR of 13.4% during the forecast period 2026–2036.
Approximately 20 million new cancer cases were diagnosed globally in 2024, driving demand for precision diagnostics.
North America holds the largest market share, estimated at approximately 45% in 2026.
Data Interpretation & Reporting Software holds the largest share among solution types.
Bioinformatics Pipelines are the fastest-growing solution segment due to the shift toward high-throughput NGS.
Advanced bioinformatics software improves analytical efficiency, automates variant interpretation, and supports more cost-effective assay development while maintaining high analytical sensitivity.
Asia-Pacific is the fastest-growing regional market, with a projected CAGR of 15.2%.
The integration of AI and machine learning is significantly improving variant detection in low-VAF samples.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2036 |
| Market Size (2026) | USD 1.40 billion |
| Market Size (2036) | USD 5.20 billion |
| CAGR (2026–2036) | 13.4% |
| Format | PDF, Excel & Cloud Portal · 267 pages |
| Segments Covered | By Solution Type: Bioinformatics Pipelines, Interpretation & Reporting, Data Management · By Technology: NGS, PCR · By Application · By End User |
| Key Companies | Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Guardant Health, Inc. (U.S.), Foundation Medicine, Inc. (U.S.), QIAGEN N.V., Roche Molecular Systems, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Sophia Genetics SA, Tempus Labs, Inc. (U.S.), Natera, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), PierianDx (Velsera) (U.S.), Fabric Genomics, Inc. (U.S.), Golden Helix, Inc. (U.S.), Strand Life Sciences, Freenome Holdings, Inc. (U.S.), GRAIL, LLC (U.S.), Exact Sciences Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ArcherDX, Inc. (Invitae) (U.S.) |
Report overview
Segments covered: solution type, technology, application, end user.
The global liquid biopsy software market is at the forefront of the precision oncology revolution, serving as the essential bridge between raw genomic data and actionable clinical insights. As cancer continues to be a leading cause of mortality worldwide with approximately 20 million new cases diagnosed in 2024 the demand for minimally invasive diagnostic tools has surged. Liquid biopsy, which analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from a simple blood draw, offers a transformative alternative to traditional tissue biopsies. However, the clinical utility of these assays is entirely dependent on sophisticated liquid biopsy bioinformatics and analytics software capable of detecting low-frequency variants amidst a vast background of healthy genetic material.
Modern oncology genomics software is designed to manage and analyze the large volumes of data generated by next-generation sequencing (NGS) platforms used in liquid biopsy workflows. Depending on sequencing depth and panel size, these workflows can generate datasets ranging from several gigabytes to hundreds of gigabytes, creating the need for robust data management, interpretation, and reporting solutions. Advanced bioinformatics pipelines automate sequence processing and variant interpretation, improving analytical efficiency and supporting more cost-effective assay development. These capabilities are particularly important for applications such as early cancer detection, where extremely low-frequency genomic alterations must be distinguished from background noise. Furthermore, the integration of precision oncology software into clinical workflows enables oncologists to identify targeted therapies and monitor treatment response and disease recurrence over time through minimal residual disease (MRD) analysis.
The market is also being shaped by the increasing regulatory clearance of companion diagnostics software. The FDA has cleared multiple liquid biopsy assays that include proprietary molecular diagnostics software for therapy selection. These tools not only automate liquid biopsy data interpretation but also ensure that reporting is standardized and compliant with global healthcare regulations. As pharmaceutical companies increasingly integrate liquid biopsy into clinical trials for biomarker discovery and patient stratification, the demand for robust cancer genomics software is expected to remain on a strong upward trajectory.
Geographically, North America is expected to lead the global liquid biopsy software market, accounting for approximately 45% of the market in 2026. This dominance is supported by a mature precision medicine ecosystem, widespread adoption of comprehensive genomic profiling, and favorable reimbursement frameworks. Meanwhile, Asia-Pacific is projected to register the fastest growth during the forecast period, with a CAGR of around 15.2%, driven by expanding genomic testing capabilities and increasing investments in precision oncology. As the broader liquid biopsy market continues to expand, software and analytics solutions are expected to play an increasingly important role in enabling data interpretation, clinical decision support, and treatment monitoring, positioning them as a high-value component of the oncology diagnostics ecosystem.
Report infographic
Market dynamics
6 factors across 5 forcesA primary driver for the liquid
biopsy software market is the rapid adoption of precision oncology and targeted therapies. As the number of FDA-approved targeted cancer treatments grows, the need for companion diagnostics software to match patients with the right therapy becomes critical. Furthermore, the increasing prevalence of cancer worldwide—expected to reach 35 million new cases annually by 2050—is creating a massive demand for minimally invasive monitoring tools. The shift toward decentralized testing in hospitals and oncology centers is also driving the need for user-friendly liquid biopsy reporting software that can be integrated directly into local clinical workflows.
Table of contents
12 chapters · 107 sections · 267 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Solution Type | Data Interpretation & Reporting | Bioinformatics Pipelines |
| By End User | Reference Laboratories | Pharmaceutical & Biotechnology Companies |
By Solution Type
- Data Interpretation & Reporting to Hold Largest Share
- The Data Interpretation & Reporting Software segment is expected to hold the largest share.
- This is because the primary value of liquid biopsy in a clinical setting lies in its ability to provide actionable reports that guide therapy selection and patient management.
- The Bioinformatics Pipelines segment is projected to witness the fastest growth, driven by the increasing complexity of NGS-based liquid biopsy assays and the need for highly sensitive algorithms to process raw sequencing data.
By End User
- Reference Laboratories to Lead, Pharma to Grow Fast
- The Reference Laboratories segment is expected to hold the largest share.
- These facilities handle the majority of high-volume clinical testing and require robust software for automated data processing and reporting.
- The Pharmaceutical & Biotechnology Companies segment is projected to witness the fastest growth.
- This reflects the surging use of liquid biopsy software in drug development, clinical trial patient enrollment, and the identification of novel biomarkers for precision oncology.
Geographic analysis
North America
Largest shareNorth America is expected to hold the largest share of the global liquid biopsy software market in 2026, accounting for approximately 45% of total revenue. This position is supported by the region's advanced precision medicine infrastructure and the fact that U.S. Medicare covers comprehensive liquid biopsy profiling for advanced cancers. The presence of leading innovators like Illumina and Guardant Health further solidifies North America's leadership position.
Europe
In Europe, Germany, the UK, and France are the key markets, driven by the rising adoption of liquid biopsy in national cancer care plans.
Asia-Pacific
Fastest growthMeanwhile, Asia-Pacific is projected to be the fastest-growing region, with a CAGR of 15.2%. China's massive patient pool and increasing investment in genomic infrastructure are primary growth drivers. The key companies operating in the Asia-Pacific market include Illumina, Thermo Fisher Scientific, and regional players like Strand Life Sciences.
Competitive landscape
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Guardant Health, Inc. (U.S.)
- Foundation Medicine, Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- Roche Molecular Systems, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Sophia Genetics SA · Switzerland
- Tempus Labs, Inc. (U.S.)
- Natera, Inc. (U.S.)
- Adaptive Biotechnologies Corporation (U.S.)
- PierianDx (Velsera) (U.S.)
- Fabric Genomics, Inc. (U.S.)
- Golden Helix, Inc. (U.S.)
- Strand Life Sciences · India
- Freenome Holdings, Inc. (U.S.)
- GRAIL, LLC (U.S.)
- Exact Sciences Corporation (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- ArcherDX, Inc. (Invitae) (U.S.)
Frequently asked questions
The market is projected to reach USD 5.2 billion by 2036, growing at a CAGR of 13.4% from 2026 to 2036.
Cite this report
Meticulous Research. (2026). Liquid Biopsy Software Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1042015). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/liquid-biopsy-software-market-6698